Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease. / Heinrich, Niels Søndergaard; Pedersen, Rune Ploegstra; Vestergaard, Mark Bitsch; Lindberg, Ulrich; Andersen, Ulrik Bjørn; Haddock, Bryan; Hansen, Tine Willum; Fornoni, Alessia; Larsson, Henrik Bo Wiberg; Rossing, Peter.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 9, 2023, p. 2605-2615.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease
AU - Heinrich, Niels Søndergaard
AU - Pedersen, Rune Ploegstra
AU - Vestergaard, Mark Bitsch
AU - Lindberg, Ulrich
AU - Andersen, Ulrik Bjørn
AU - Haddock, Bryan
AU - Hansen, Tine Willum
AU - Fornoni, Alessia
AU - Larsson, Henrik Bo Wiberg
AU - Rossing, Peter
N1 - Publisher Copyright: © 2023 John Wiley & Sons Ltd.
PY - 2023
Y1 - 2023
N2 - Aim: To investigate the effects of ezetimibe on the urine albumin creatinine ratio (UACR) and kidney parenchyma fat content (kidney-PF) in individuals with type 2 diabetes (T2D) and early chronic kidney disease. Materials and Methods: A randomized, double-blind, placebo-controlled study of ezetimibe 10 mg once daily for 16 weeks in individuals with T2D and a UACR of 30 mg/g or higher was conducted. Kidney-PF was assessed with magnetic resonance spectroscopy. Geometric mean changes from baseline were derived from linear regressions. Results: A total of 49 participants were randomized to ezetimibe (n = 25) or placebo (n = 24). Overall, mean ± standard deviation age was 67 ± 7 years, body mass index was 31 ± 4 kg/m2 and the proportion of men was 84%. The mean estimated glomerular filtration rate was 76 ± 22 mL/min/1.73m2 and median (first-third quartile) UACR was 95 (41-297) mg/g. Median kidney-PF was 1.0% (0.3%-2.1%). Compared with placebo, ezetimibe did not significantly reduce UACR (mean [95% confidence interval] change: −3% [−28%-31%]) or kidney-PF (mean change: −38% [−66%-14%]). In participants with baseline kidney-PF above the median, ezetimibe reduced kidney-PF significantly (mean change: −60% [−84%-−3%]) compared with placebo, while the reduction in UACR was not significant (mean change: −28% [−54%-15%]). Conclusions: Ezetimibe did not reduce the UACR or kidney-PF on top of modern T2D management. However, kidney-PF was reduced with ezetimibe in participants with high baseline kidney-PF.
AB - Aim: To investigate the effects of ezetimibe on the urine albumin creatinine ratio (UACR) and kidney parenchyma fat content (kidney-PF) in individuals with type 2 diabetes (T2D) and early chronic kidney disease. Materials and Methods: A randomized, double-blind, placebo-controlled study of ezetimibe 10 mg once daily for 16 weeks in individuals with T2D and a UACR of 30 mg/g or higher was conducted. Kidney-PF was assessed with magnetic resonance spectroscopy. Geometric mean changes from baseline were derived from linear regressions. Results: A total of 49 participants were randomized to ezetimibe (n = 25) or placebo (n = 24). Overall, mean ± standard deviation age was 67 ± 7 years, body mass index was 31 ± 4 kg/m2 and the proportion of men was 84%. The mean estimated glomerular filtration rate was 76 ± 22 mL/min/1.73m2 and median (first-third quartile) UACR was 95 (41-297) mg/g. Median kidney-PF was 1.0% (0.3%-2.1%). Compared with placebo, ezetimibe did not significantly reduce UACR (mean [95% confidence interval] change: −3% [−28%-31%]) or kidney-PF (mean change: −38% [−66%-14%]). In participants with baseline kidney-PF above the median, ezetimibe reduced kidney-PF significantly (mean change: −60% [−84%-−3%]) compared with placebo, while the reduction in UACR was not significant (mean change: −28% [−54%-15%]). Conclusions: Ezetimibe did not reduce the UACR or kidney-PF on top of modern T2D management. However, kidney-PF was reduced with ezetimibe in participants with high baseline kidney-PF.
KW - chronic kidney disease
KW - ectopic kidney fat
KW - ezetimibe
KW - magnetic resonance
KW - type 2 diabetes
U2 - 10.1111/dom.15146
DO - 10.1111/dom.15146
M3 - Journal article
C2 - 37278273
AN - SCOPUS:85161507835
VL - 25
SP - 2605
EP - 2615
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 9
ER -
ID: 365704088